News

# CureVac stock drops more than 50% on news trial COVID vaccine 47% effective

Table of Contents

“#
CureVac stock drops more than 50% on news trial COVID vaccine 47% effective
”

Shares of Curevac NV tanked more than 50% in the extended session Wednesday after the pharma company said its trial COVID-19 vaccine showed an efficacy of 47% against the illness.

Curevac’s
CVAC,
-3.47%
messenger RNA-based vaccine would compete with similar vaccines from Pfizer and BioNTech as well as Moderna, which have shown efficacy above 90% and have already been distributed to millions of people across the globe.

Claudia Assis

If you liked the article, do not forget to share it with your friends. Follow us on Google News too, click on the star and choose us from your favorites.